Molecular Formula | C8H11NO4 |
Molar Mass | 185.18 |
Density | 1.569 |
Melting Point | 270-271 °C |
Boling Point | 376.4±32.0 °C(Predicted) |
Flash Point | 181.4°C |
Vapor Presure | 1.06E-06mmHg at 25°C |
pKa | 2.06±0.40(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,2-8°C |
Refractive Index | 1.619 |
In vitro study | Eglumegad (LY354740) down-regulates spots 1014, 1822 (hypoxia up-regulated protein 1), 4513 (an isoform of protein disulfide isomerase 3), 6204, 6312, 7306 (26S proteasome non-ATPase regulatory subunit 7) and protein spots 1013 and 6005 (destrin), and up-regulates spot 6507 (collapsin response mediator protein 1) in mouse cortical neurons. |
In vivo study | Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) has no effect on spatial working memory performance in Gria1 −/− or WT mice, and it has no effect on rewarded alternation testing with a short inter-trial interval in Gria1 −/− and WT mice at concentration of 30 mg/kg. Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) reduces spontaneous locomotor activity in wild-type and Gria1 −/− mice. Eglumegad (LY354740) (15 mg/kg, i.p.) dreases novelty-induced hyperlocomotion in naive GluA1-KO and pre-handled GluA1-KO males, but not in females. Eglumegad (LY354740) (15 mg/kg, i.p.) significantly reduces the increased c-Fos expression of GluA1-KO males to the level of WT males, but not in of females. Eglumegad (LY354740) (10 mg/kg, i.p.) attenuates the immobilization stress-induced increase in BDNF mRNA expression in the rat mPFC. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 5.4 ml | 27.001 ml | 54.002 ml |
5 mM | 1.08 ml | 5.4 ml | 10.8 ml |
10 mM | 0.54 ml | 2.7 ml | 5.4 ml |
5 mM | 0.108 ml | 0.54 ml | 1.08 ml |
biological activity | Eglumegad (LY354740) is an effective and selective group II (mGlu2/3) receptor agonist with IC50 of 5 and 24 nM for human mGlu2 and mGlu3 receptors, respectively. |